Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2020 - 2026)

Monte Rosa Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $25.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 57.14% year-over-year to $25.6 million; the TTM figure through Mar 2026 stood at $25.6 million (up 57.14% YoY), while the FY2025 annual figure was $26.7 million, up 42.1% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $25.6 million, down from $26.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $26.7 million in Q4 2025, with the low at $3.2 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $9.0 million (2022), against an average of $11.8 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 53.73% in 2024, then jumped 360.21% in 2025.
• Monte Rosa Therapeutics' Accumulated Expenses stood at $14.6 million in 2022, then tumbled by 47.92% to $7.6 million in 2023, then jumped by 147.4% to $18.8 million in 2024, then soared by 42.1% to $26.7 million in 2025, then fell by 4.12% to $25.6 million in 2026.
• Business Quant data shows GLUE's Accumulated Expenses at $25.6 million in Q1 2026, $26.7 million in Q4 2025, and $17.9 million in Q3 2025.